| Prev Close | 294.61 |
| Open | 294.12 |
| Day Low/High | 292.50 / 295.57 |
| 52 Wk Low/High | 281.89 / 543.55 |
| Volume | 637.43K |
| Avg Volume | 881.70K |
| Exchange | NASDAQ |
| Shares Outstanding | 105.95M |
| Market Cap | 31.99B |
| EPS | 11.30 |
| P/E Ratio | 23.93 |
| Div & Yield | N.A. (N.A) |
The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Jim Cramer weighs in on Waste Management, Blackstone Group, Xilinx, Celgene, Nvidia, Exelixis, Moneygram and more.
Jim Cramer thinks that, finally, bargain hunters are just saying, "Enough already! It can't be that bad."
Thanks to the stock market correction many world-class stocks are back down to attractive levels.
Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases
Findings validate importance of large-scale human genetics effort undertaken by Regeneron Genetics Center; provide target for potential development of new medicines
The beaten down biotech sector may offer more opportunities in this newly volatile market environment.
Jim Cramer maps out what investors need to find a way back to the upside, including the Fed, interest rates and earnings.
Expect U.S. regulatory submission for diabetic retinopathy later this year
Jim Cramer takes a closer look at Walt Disney Co., RH, Immunogen, and Advanced Micro Devices.
In the wake of Trump's blocking the Broadcom-Qualcomm deal, Jim Cramer ask if we should be worried that all of tech that wants to be big in China could be under pressure.
Top Projects at Nation's Oldest and Most Prestigious STEM Competition for High School Seniors Have Potential Implications for Agricultural Science, Public Health and Medical Diagnosis
Top Projects at Nation's Oldest and Most Prestigious STEM Competition for High School Seniors Have Potential Implications for Agricultural Science, Public Health and Medical Diagnosis
Jim Cramer looks at the investment strategies you need to use throughout your life, especially in a volatile market.
Jim Cramer asks: Is every one of these vexing VIX derivatives going to have to go bust before this torture ends? Looks like it.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Jim Cramer highlights Anthem, A.O. Smith, Tableau Software, Electro Scientific Industries, CRISPR Therapeutics.
Jim Cramer says this is the scary process that gets us back to where we can maintain a real, not parabolic, advance.
Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. Science and Mathematics Competition for High School Seniors
Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. Science and Mathematics Competition for High School Seniors
Jim Cramer is bullish on Floor & Decor, Chegg, Core Labs, Cedar Fair, Newmark Group, First Solar.
Jim Cramer says this market's odd-couple behavior is worth investigating because it can push stocks even higher.
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
These favorite names in the volatile sector offer the potential for high rewards.
Jim Cramer highlights T-Mobile US, Take-Two Interactive, Activision Blizzard, Owens Corning and more.
Weakness has been a clarion call to sell for so many, when it's really the buying opportunity that so few people recognize.
